KBB-N1

KBB-N1 is an **ultra-low molecular weight ginsenoside compound K derivative** developed as a novel therapeutic agent for multiple myeloma. It is a **triterpene compound** that demonstrates **minimal toxicity to hematopoietic stem cells and major organs**, making it particularly suitable for elderly patients with multiple myeloma. The compound works by **increasing the expression of phosphorylated p53**, thereby activating the p53 apoptosis pathway in myeloma cells. This mechanism leads to PARP cleavage and caspase activation, ultimately inducing apoptosis in malignant plasma cells. Preclinical studies have shown that KBB-N1 exhibits significantly less toxicity than standard treatments like lenalidomide - no suppression of normal hematopoietic stem cell function was observed at doses up to 60 μM, while lenalidomide showed severe suppression at 25 μM. In animal models, KBB-N1 demonstrated significant tumor growth inhibition and prolonged survival times when administered either orally (20 mg/kg/day) or intravenously (7 mg/kg/day). Molecular docking studies revealed optimal binding conformation with phosphorylated p53 with a docking score of -7.6 kcal/M.

Other names

ultra-low molecular weight ginsenoside compound K